Role of sentinel lymph node biopsy with indocyanine green and site of injection in endometrial cancer.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
ppublish
Résumé
The aim of the present narrative review is to summarize the state of art on sentinel lymph node biopsy (SLNB) in endometrial cancer, with a special focus on indocyanine green (ICG) as adopted tracer. Over the years, the surgical nodal staging in patients with endometrial cancer has been intensively investigated. Traditionally, systematic pelvic and para-aortic lymphadenectomy represented the gold standard surgical treatment to assess nodal involvement of the tumor. Through the last two decades, SLNB has gradually replaced lymphadenectomy as a more targeted procedure. A great heterogeneity of tracers and injection techniques have been proposed to perform SLNB. However, no universally accepted recommendations are still available. SLNB has nowadays almost replaced pelvic lymphadenectomy in low-risk endometrial cancers, offering a better safety profile while being related to a comparable nodal involvement sensitivity. Currently, ICG is considered to be the most used tracer among others. Different injection sites have been proposed, with different detection features. While ICG cervical injection is nowadays the suggested technique for SLNB, noncervical injection techniques, such as hysteroscopic and combined procedures, seem to have a better accuracy in para-aortic nodal assessment, which have a role in high-risk endometrial cancers.
Identifiants
pubmed: 39106403
doi: 10.1097/CCO.0000000000001075
pii: 00001622-202409000-00010
doi:
Substances chimiques
Indocyanine Green
IX6J1063HV
Coloring Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-390Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31:12–39.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249.
Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer. Int J Gynecol Obstet 2023; 162:383–394.
Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73.
Holloway RW, Abu-Rustum NR, Backes FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017; 146:405–415.
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin 2017; 67:93–99.
Proppe L, Alkatout I, Koch R, et al. Impact of lymphadenectomy on short- and long-term complications in patients with endometrial cancer. Arch Gynecol Obstet 2022; 306:811–819.
Bohrer JC, Walters MD, Park A, et al. Pelvic nerve injury following gynecologic surgery: a prospective cohort study. Am J Obstet Gynecol 2009; 201:531.e1–531.e7.
Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714–718.
Jakobsen JK. Sentinel node methods in penile cancer – a historical perspective on development of modern concepts. Semin Nucl Med 2022; 52:486–497.
Zivanovic O, Khoury-Collado F, Abu-Rustum NR, Gemignani ML. Sentinel lymph node biopsy in the management of vulvar carcinoma, cervical cancer, and endometrial cancer. Oncologist 2009; 14:695–705.
Helgers RJA, Winkens B, Slangen BFM, Werner HMJ. Lymphedema and post-operative complications after sentinel lymph node biopsy versus lymphadenectomy in endometrial carcinomas—a systematic review and meta-analysis. J Clin Med 2020; 10:E120.
Yu R, Matthews BJ, Beavis AL. The role of sentinel lymph node mapping in high-grade endometrial cancer. Curr Treat Options Oncol 2022; 23:1339–1352.
Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017; 18:384–392.
Frumovitz M, Plante M, Lee PS, et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, noninferiority trial. Lancet Oncol 2018; 19:1394–1403.
Nagar H, Wietek N, Goodall RJ, et al. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. Cochrane Database Syst Rev 2021; 6:CD013021.
Wang Q, Wang B, Wang L, et al. The efficiency of a combined injection technique for sentinel lymph node mapping in intermediate-high-risk endometrial cancer. J Surg Oncol 2021; 124:1551–1560.
Burg LC, Verheijen S, Bekkers RLM, et al. The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis. J Gynecol Oncol 2022; 33:e66.
Kessous R, How J, Abitbol J, et al. Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignment. Int J Gynecol Cancer 2019; 29:1121–1125.
Zapardiel I, Alvarez J, Barahona M, et al. Utility of intraoperative fluorescence imaging in gynecologic surgery: systematic review and consensus statement. Ann Surg Oncol 2021; 28:3266–3278.
Stämpfli CAL, Papadia A, Mueller MD. From systematic lymphadenectomy to sentinel lymph node mapping: a review on transitions and current practices in endometrial cancer staging. Chin Clin Oncol 2021; 10:22.
How J, Gotlieb WH, Press JZ, et al. Comparing indocyanine green, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol 2015; 137:436–442.
Daraï E, Dubernard G, Bats AS, et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 2015; 136:54–59.
Papadia A, Garbade A, Gasparri ML, et al. Minimally invasive surgery does not impair overall survival in stage IIIC endometrial cancer patients. Arch Gynecol Obstet 2020; 301:585–590.
Rozenholc A, Samouelian V, Warkus T, et al. Green versus blue: randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer. Gynecol Oncol 2019; 153:500–504.
Cabrera S, Barahona-Orpinell M, Almansa-González C, et al. Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: results of the COMBITEC study. Gynecol Oncol 2021; 162:32–37.
Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol 2012; 30:3786–3791.
Food and Drug Administration. Fada label-indocyanine green (intravenous route). 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011525s027lbl.pdf.
Ji Q, Wang X, Jiang J, Chen L. Sentinel lymph node mapping in high-risk endometrial cancer: a systematic review and meta-analysis. Gland Surg 2020; 9:2091–2105.
Reinhart MB, Huntington CR, Blair LJ, et al. Indocyanine green. Surg Innov 2016; 23:166–175.
Gasparri ML, Caserta D, Benedetti Panici P, et al. Surgical staging in endometrial cancer. J Cancer Res Clin Oncol 2019; 145:213–221.
Plante M, Touhami O, Trinh XB, et al. Sentinel node mapping with indocyanine green and endoscopic near-infrared fluorescence imaging in endometrial cancer. A pilot study and review of the literature. Gynecol Oncol 2015; 137:443–447.
Desmettre T, Devoisselle JM, Mordon S. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv Ophthalmol 2000; 45:15–27.
Alander JT, Kaartinen I, Laakso A, et al. A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging 2012; 2012:940585.
Obana A, Miki T, Hayashi K, et al. Survey of complications of indocyanine green angiography in Japan. Am J Ophthalmol 1994; 118:749–753.
Hope-Ross M, Yannuzzi LA, Gragoudas ES, et al. Adverse reactions due to indocyanine green. Ophthalmology 1994; 101:529–533.
Grischke EM, Röhm C, Hahn M, et al. ICG fluorescence technique for the detection of sentinel lymph nodes in breast cancer: results of a prospective open-label clinical trial. Geburtshilfe Frauenheilkd 2015; 75:935–940.
Guo J, Yang H, Wang S, et al. Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol 2017; 15:196.
Frumovitz M, Coleman RC, Soliman PT, et al. A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecol Oncol 2014; 132:275–279.
AlHilli MM, Mariani A. Preoperative selection of endometrial cancer patients at low risk for lymph node metastases: useful criteria for enrollment in clinical trials. J Gynecol Oncol 2014; 25:267–269.
Bogani G, Dowdy SC, Cliby WA, et al. Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 2014; 40:301–311.
AlHilli MM, Podratz KC, Dowdy SC, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol 2013; 131:103–108.
Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008; 109:11–18.
Kumar S, Podratz KC, Bakkum-Gamez JN, et al. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol 2014; 132:38–43.
Todo Y, Suzuki Y, Azuma M, et al. Ultrastaging of para-aortic lymph nodes in stage IIIC1 endometrial cancer: a preliminary report. Gynecol Oncol 2012; 127:532–537.
Bogani G, Giannini A, Vizza E, et al. Sentinel node mapping in endometrial cancer. J Gynecol Oncol 2024; 35:
Khoury-Collado F, Glaser GE, Zivanovic O, et al. Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? Gynecol Oncol 2009; 115:453–455.
Bogani G, Murgia F, Ditto A, Raspagliesi F. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol 2019; 153:676–683.
Martinelli F, Ditto A, Signorelli M, et al. Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: a single center evaluation over 200 cases. Gynecol Oncol 2017; 146:525–530.
Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with lynch syndrome. J Clin Oncol 2008; 26:5965–5971.
Maccauro M, Lucignani G, Aliberti G, et al. Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer. Eur J Nucl Med Mol Imaging 2005; 32:569–574.
Solima E, Martinelli F, Ditto A, et al. Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. Gynecol Oncol 2012; 126:419–423.
Martinelli F, Ditto A, Bogani G, et al. Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers. Int J Gynecol Cancer 2020; 30:332–338.
Rossi EC, Jackson A, Ivanova A, Boggess JF. Detection of sentinel nodes for endometrial cancer with robotic assisted fluorescence imaging: cervical versus hysteroscopic injection. Int J Gynecol Cancer 2013; 23:1704–1711.
Ditto A, Casarin J, Pinelli C, et al. Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: a multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. Eur J Cancer 2020; 140:1–10.
Ruiz R, Gorostidi M, Jaunarena I, et al. Maximizing sentinel node detection in endometrial cancer with dual cervical and transcervical fundal indocyanine green injection: 5-year single-center prospective study. Eur J Obstet Gynecol Reprod Biol 2021; 261:59–64.
Eoh KJ, Lee YJ, Kim HS, et al. Two-step sentinel lymph node mapping strategy in endometrial cancer staging using fluorescent imaging: a novel sentinel lymph node tracer injection procedure. Surg Oncol 2018; 27:514–519.
Gorostidi M, Ruiz R, Cespedes J, et al. Aortic sentinel node detection in endometrial cancer: 6 year prospective study. J Gynecol Obstet Hum Reprod 2023; 52:102584.
Kim YN, Eoh KJ, Lee JY, et al. Comparison of outcomes between the one-step and two-step sentinel lymph node mapping techniques in endometrial cancer. Int J Gynecol Cancer 2020; 30:318–324.
Leone Roberti Maggiore U, Spanò Bascio L, Alboni C, et al. Sentinel lymph node biopsy in endometrial cancer: when, how and in which patients. Eur J Surg Oncol 2024; 50:107956.
Emons G, Kim JW, Weide K, et al. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6). Int J Gynecol Cancer 2021; 31:1075–1079.
Guan J, Xue Y, Zang R, et al. Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: trial protocol for a noninferiority randomized controlled trial (SNEC trial). J Gynecol Oncol 2021; 32:e60.
Park JY, Kim JH, Baek MH, et al. Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer: a Korean Gynecologic Oncology Group trial (KGOG2029/SELYE). J Gynecol Oncol 2022; 33:e73.